label - Food and Drug Administration
UZEDY is an atypical antipsychotic indicated for the treatment of schizophrenia in adults. (1) Administer UZEDY by subcutaneous injection in the abdomen or upper arm by a healthcare...
UZEDY is an atypical antipsychotic indicated for the treatment of schizophrenia in adults. (1) DOSAGE AND ADMINISTRATION • Establish tolerability with oral risperidone prior to initiating UZEDY. (2.1) • Administer UZEDY by subcutaneous injection in the abdomen or upper arm by a healthcare professional. Do not administer by any other route ...
UZEDY® (risperidone) extended-release injectable suspension
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Administration & Dosing | UZEDY® (risperidone) extended …
UZEDY® (risperidone) extended-release injectable suspension administration information. View a video on how to prepare and administer UZEDY. Please see full Prescribing Information, including Boxed WARNING for UZEDY.
Uzedy: Uses, Dosage, Side Effects, Warnings - Drugs.com
2023年7月12日 · What is Uzedy? Uzedy injection is an extended-release injectable suspension used in adults to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Uzedy belongs to a class of medications called atypical antipsychotics.
UZEDY (Teva Pharmaceuticals USA, Inc.): FDA Package Insert
2025年1月24日 · UZEDY is indicated for the treatment of schizophrenia in adults. For patients who have never taken risperidone, establish tolerability with oral risperidone prior to initiating UZEDY. UZEDY must be administered by a healthcare professional as an abdominal or upper arm subcutaneous injection. Do not administer UZEDY by any other route.
皮下注射的利培酮长效针剂，了解一下 | 新药资讯_腾讯新闻
2023年11月14日 · Uzedy采用MedinCell的SteadyTeq™共聚物技术，单剂给药后6-24小时内达到治疗所需血药浓度，无需利培酮负荷剂量或联用口服利培酮，但使用前同样需要 ...
UZEDY-美国FDA药品数据库-药物在线
商品名:UZEDY,活性成分:RISPERIDONE,申请号:213586,申请人:TEVA. 药品注册申请号：213586. 申请类型：NDA (新药申请) 申请人：TEVA. 申请人全名：TEVA NEUROSCIENCE INC. ... Labeling-Container/Carton Labels: STANDARD Letter. 与本品相关的专利信息（来自FDA橙皮书Orange Book） ...
Uzedy™ (risperidone) – New drug approval • On April 28, 2023, Teva Neuroscience and MedinCell announced the FDA approval of Uzedy (risperidone) subcutaneous injection, for the treatment of schizophrenia in adults . • Risperidone is available generically as an oral tablet, oral solution, and orally disintegrating tablets,
• Risperidone SC 1-2 month (UZEDY) is indicated for the treatment of s chizophrenia in adults. Dosage Form(s) Under Review 1 • Extended-release injectable suspension: 50 mg/0.14 mL; 75 mg/0.21 mL; 100 mg/0.28 mL; 125 mg/0.35 mL; 150 mg/0.42 mL; 200 mg/0.56 mL; 250 mg/0.7 mL single-dose pref illed syringes. Clinical Evidence Summary
- 某些结果已被删除